Ancell

anti-CD272 [BTLA] (human), mAb (ANC6E9)

CHF 306.00

In stock

ANC-272-020100 µgCHF 306.00

More Information
Product Details
Synonyms	BTLA; B- and T-lymphocyte Attenuator
Product Type	Monoclonal Antibody
Properties
Clone	ANC6E9
Isotype	Mouse IgG1κ
Immunogen/Antigen	Recombinant extracellular human CD272.
Application	ELISA Flow Cytometry Functional Application
Crossreactivity	Human
Formulation	50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate
Isotype Negative Control	Mouse IgG1 Isotype Control
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
Declaration	Manufactured by Ancell Corporation.
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS	Inquire
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Human CD272 (BTLA; B and T Lymphocyte Attenuator) is a member of the immunoglobulin superfamily and has sequence homology to PD-1 and CTLA-4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand CD270 (HVEM) can downregulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines. Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis.

Call	+41 61 926 6040
Fax	+41 61 926 6049